Barclays
RIGL icon

Barclays’s Rigel Pharmaceuticals RIGL Stock Holding History

Barclays’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-9,800
Closed -$277K – 7347
2018
Q2 		$277K Buy
+9,800
New +$349K ﹤0.01% 4449
2016
Q4 		– Sell
-40
Closed -$1K – 6792
2016
Q3 		$1K Sell
40
-500
-93% -$14.3K ﹤0.01% 6426
2016
Q2 		$12K Buy
+540
New +$13.4K ﹤0.01% 5479
2015
Q3 		– Sell
-1,010
Closed -$30K – 7007
2015
Q2 		$30K Buy
1,010
+970
+2,425% +$37.1K ﹤0.01% 5443
2015
Q1 		$1K Buy
+40
New +$1.1K ﹤0.01% 6987
2014
Q4 		– Sell
-300
Closed -$3K – 7545
2014
Q3 		$3K Sell
300
-130
-30% -$3.67K ﹤0.01% 7325
2014
Q2 		$13K Sell
430
-1,210
-74% -$41.1K ﹤0.01% 6706
2014
Q1 		$49K Buy
1,640
+1,420
+645% +$50.6K ﹤0.01% 6016
2013
Q4 		$4K Sell
220
-1,490
-87% -$43.7K ﹤0.01% 7221
2013
Q3 		$51K Sell
1,710
-230
-12% -$8.39K ﹤0.01% 6052
2013
Q2 		$65K Buy
+1,940
New +$87.9K ﹤0.01% 6117

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's RIGL Position: Q2 2026 in Review

Barclays reduced its Rigel Pharmaceuticals (RIGL) stake by 8.3% in Q2 2026, selling an estimated $39K and leaving 13,933 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #3163.

Barclays first reported a position in RIGL in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.28M in Q1 2018. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Barclays held 13,933 shares of Rigel Pharmaceuticals worth $545K as of Q2 2026.
  • Barclays sold 1,265 Rigel Pharmaceuticals shares in Q2 2026, an estimated $39K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3163 holding.
  • Barclays first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Rigel Pharmaceuticals position peaked at $3.28M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.